The most important finding of this study was the possible role of the serum level of the cytokine IL-4 as a circulating biomarker for TA-specific T cell responses in treatment-naïve patients with resectable NSCLC (n = 36; Figure S1). This evidence concerns the gene IL4 and non-small cell lung carcinoma.